Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | COLUMBA: SC vs IV daratumumab in R/R multiple myeloma

Joan Bladé • 15 Jun 2019
EHA 2019
Multiple Myeloma
COLUMBA

Joan Bladé, MD, Hospital Clinic, Barcelona, Spain, discusses the use of subcutaneous daratumumab compared to intravenous daratumumab in the treatment of relapsed/refractory multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Joan Bladé

2:36
Looking forward to ISA 2022
Joan Bladé • 12 May 2022
1:02
How the amyloidosis treatment landscape has transformed in recent years
Joan Bladé • 12 May 2022
3:26
Managing and treating renal impairment in multiple myeloma
Joan Bladé • 12 May 2022
3:05
Amyloidosis classification and epidemiology
Joan Bladé • 4 Sep 2020

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals